Abstract
Overview
Introduction
The face of ACS is changing. The ageing population and pressure of growing
risk factors have made a significant impact on the management strategies in
ACS. This report unveils the true picture through in-depth analysis of data on
over 21,000 ACS patient records in the 5 major European pharmaceutical markets
(5EU; France, Germany, Italy, Spain and the UK).
Scope
- What are the current definitions, diagnostic methods and treatment
approaches of the disease?
- To what extent are reperfusion therapies, such as PCI (percutaneous
coronary intervention) and/or thrombolysis, used?
- What is the current role of pre-hospital thrombolysis and how is this
likely to change in the future?
- What are the current hospital admission and logistics issues?
Report Highlights
Costs are no longer the restraining or dominant driver of a specific
pharmacological strategy. Datamonitor' s findings show that the routine use of
troponins as cardiac markers has aided this development, with almost 90% of
all ACS patients receiving tests for either troponin I or troponin T across
the 5EU.
A new definition for myocardial infarction has shifted a significant number of
patients from unclear diagnosis of unstable angina to myocardial infarction
moving from an essentially conservative and observational approach to an
increase in more aggressive treatment strategies.
Advances in novel imaging techniques provide opportunities to diagnose and
treat the most complex ACS cases, however, inter-hospital logistics, necessary
specialist training and cost constraints continue to prevent hospitals and
clinicians from regular use of those diagnostic methods.
Reasons to Purchase
- Understand current definitions, diagnostic methods and treatment
approaches in ACS
- Quantify current dynamics of hospital logistics, conservative therapies
and reperfusion therapies, such as PCI and thrombolysis
- Unveil the in-depth influencing factors leading to selection of specific
pharmacological and interventional strategies
View Cart
